If you started a blood pressure medication and noticed erectile function declining, you're not imagining things. Some antihypertensives are well-documented ED culprits. Others are essentially neutral. And a few — counterintuitively — might actually improve erectile function by treating the vascular disease that caused ED in the first place.
The ED-Causing Classes
Thiazide Diuretics (Worst Offender)
Hydrochlorothiazide (HCTZ) and chlorthalidone are the most commonly prescribed first-line blood pressure medications — and they're also the antihypertensives most associated with ED. Studies report ED rates of 10–20% in men on thiazide diuretics, compared to 3–5% on placebo.
The mechanism isn't fully understood, but likely involves reduced zinc levels (zinc is essential for testosterone production), decreased blood flow to the penis, and direct smooth-muscle effects. If you started a thiazide and noticed ED developing within weeks or months, the association is strong.
Non-Selective Beta-Blockers
Propranolol and atenolol are the classic offenders. Older, non-selective beta-blockers reduce cardiac output and can blunt the sympathetic arousal response involved in erectile function. Reported ED rates range from 5–15%.
Newer, selective beta-blockers like nebivolol tell a different story — more on that below.
Centrally-Acting Agents
Clonidine and methyldopa (Aldomet) affect ED through central nervous system mechanisms. These are less commonly prescribed today but still used in some cases. ED rates on these medications can be as high as 20–40%.
The Neutral or Beneficial Classes
ACE Inhibitors (Neutral to Positive)
Lisinopril, enalapril, ramipril, and other ACE inhibitors are generally considered neutral for sexual function. Some data suggests they may modestly improve erectile function by reducing angiotensin II (which constricts blood vessels, including penile arteries). They're a solid choice for hypertensive men concerned about ED.
ARBs (Likely Beneficial)
Losartan, valsartan, irbesartan — angiotensin receptor blockers consistently show neutral or positive effects on sexual function in clinical trials. Losartan in particular has data suggesting improved sexual function in hypertensive men, possibly through enhanced nitric oxide bioavailability.
If you're on a thiazide or beta-blocker and experiencing ED, asking your prescriber about switching to an ARB is a reasonable evidence-based conversation.
Nebivolol (Uniquely Positive)
Nebivolol is a third-generation beta-blocker that's pharmacologically distinct from propranolol and atenolol. It selectively blocks beta-1 receptors (sparing beta-2) and directly stimulates nitric oxide release in blood vessels. Multiple studies show it either preserves or improves erectile function compared to older beta-blockers.
For men who need a beta-blocker and have ED concerns, nebivolol is the evidence-based choice.
Calcium Channel Blockers (Generally Neutral)
Amlodipine, nifedipine, and diltiazem are generally neutral for sexual function. They work by relaxing vascular smooth muscle — a mechanism that's theoretically compatible with erectile function. Note: diltiazem and verapamil are moderate CYP3A4 inhibitors, which means they can increase PDE5 inhibitor blood levels. Dose adjustments may be needed.
The Decision Framework
| If You're Taking | ED Risk | Consider Switching To |
|---|---|---|
| HCTZ / Chlorthalidone | High | ARB or ACE inhibitor |
| Propranolol / Atenolol | Moderate-High | Nebivolol or ARB |
| Clonidine / Methyldopa | High | ARB or CCB |
| ACE Inhibitor | Low | Stay; add ED treatment if needed |
| ARB (Losartan, etc.) | Very Low | Stay; may improve ED |
| Amlodipine | Low | Stay; add ED treatment if needed |
Important: Never stop or switch a blood pressure medication on your own. Uncontrolled hypertension itself damages blood vessels and worsens ED long-term. The goal is optimizing your regimen with your prescriber — not abandoning treatment.
Adding ED Medication to Your Antihypertensive
PDE5 inhibitors can be safely used with most antihypertensives. The additive blood pressure reduction is generally modest — about 5–8 mmHg systolic in most studies. Your prescriber should be aware you're taking both, and starting at a lower PDE5 inhibitor dose is prudent.
The exceptions: alpha-blockers (covered in a separate guide) and nitrates (absolutely contraindicated with all PDE5 inhibitors).